Adversarial Injection · Alpelisib (Piqray; BYL719; NDA 212526; CAS 1217486-61-7; MW ~441.5 g/mol; C19H22F3N5O2S; aminothiazole + trifluoromethyl + morpholinopiperidine scaffold [FORTIETH MECHANISM CLASS in Glyphward 591-attack portfolio — FIRST PI3Kα (PIK3CA CATALYTIC SUBUNIT)-SELECTIVE KINASE INHIBITOR EVER FDA APPROVED: PI3Kα (PIK3CA) IC50 ~5 nM; PI3Kβ IC50 ~1,156 nM; PI3Kγ IC50 >8,000 nM; PI3Kδ IC50 >7,000 nM (>200-fold selectivity for PI3Kα over PI3Kβ; >1,600-fold over PI3Kγ; >1,400-fold over PI3Kδ); PRIOR PI3K INHIBITORS: idelalisib (Zydelig; NDA 205858; July 2014) = PI3Kδ-selective (B-cell malignancies); copanlisib (Aliqopa; NDA 209936; September 2017) = pan-PI3K (IV only; follicular lymphoma); no prior PI3Kα-selective isoform-specific inhibitor existed in any solid tumor indication before alpelisib; FIRST KINASE INHIBITOR SPECIFICALLY TARGETING PIK3CA MUTATIONS IN SOLID TUMORS: PIK3CA (Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha; PIK3CA gene on chromosome 3q26.32) is mutated in ~40% of HR+/HER2- breast cancer; common activating mutations: E542K (helical domain); E545K (helical domain); H1047R (kinase domain; most common; >50% of PIK3CA mutations in BC); PIK3CA hotspot mutations activate p110α (PI3Kα catalytic subunit) constitutively; COMPANION DIAGNOSTIC: therascreen PIK3CA RGQ PCR Kit (Qiagen; detects 11 PIK3CA hotspot mutations in ctDNA from plasma or tumor tissue biopsy; companion diagnostic required for alpelisib use per FDA labeling); UNIQUE TOXICITY: GRADE 3/4 HYPERGLYCEMIA (~36% WITHOUT PROPHYLAXIS): PI3K-AKT pathway controls insulin receptor substrate (IRS-1) phosphorylation in insulin-responsive tissues (liver, skeletal muscle, adipose); alpelisib inhibits PI3Kα in these tissues = impairs insulin receptor downstream signaling = iatrogenic insulin resistance = fasting hyperglycemia + postprandial glucose spikes; NO OTHER KINASE INHIBITOR IN 591-ATTACK PORTFOLIO HAS HYPERGLYCEMIA AS PRIMARY DOSE-LIMITING TOXICITY MECHANISM (afatinib, erlotinib, gefitinib = acneiform rash; osimertinib = QTc; CDK4/6 inhibitors = neutropenia; VEGFR inhibitors = hypertension; MEK inhibitors = ocular toxicity; alpelisib = hyperglycemia unique among all); requires baseline fasting glucose and HbA1c before starting; prophylactic metformin recommended for pre-diabetic/diabetic patients; antihyperglycemic monitoring protocol; SOLAR-1 PHASE 3: PIK3CA-mutated cohort: PFS HR 0.65 (11.0 vs 5.7 months; p<0.001); ORR 26.6% vs 12.8%; OS HR 0.86 (final OS analysis; not statistically significant); alpelisib 300 mg QD + fulvestrant 500 mg IM q28d vs placebo + fulvestrant; NDA 212526 STANDARD APPROVAL MAY 24 2019 (not accelerated — full approval based on SOLAR-1 PFS); NOVARTIS BYL719: BYL719 = Novartis Institutes for BioMedical Research (NIBR) internal compound designation; developed at Novartis NIBR Basel; aminothiazole scaffold with trifluoromethyl substituent; SECOND NOVARTIS KINASE CLASS IN PORTFOLIO (imatinib [BCR-ABL; NIBR] + ribociclib [CDK4/6; NIBR] + lapatinib [via GSK acquisition] + alpelisib [PI3Kα; NIBR] = multiple Novartis kinase classes); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · Fortieth Mechanism Class First PI3Kα-Selective Kinase Inhibitor Ever + First PIK3CA Mutation-Targeted Kinase in Solid Tumors + Unique Hyperglycemia Metabolic Toxicity (No Other Kinase) + SOLAR-1 PFS HR 0.65 + Companion Diagnostic therascreen PIK3CA · Attack #591

Alpelisib (aminothiazole + trifluoromethyl + morpholinopiperidine scaffold; Piqray; BYL719; NDA 212526; CAS 1217486-61-7; MW ~441.5 g/mol; C19H22F3N5O2S; [FORTIETH MECHANISM CLASS: FIRST PI3Kα (PIK3CA)-SELECTIVE KINASE INHIBITOR EVER FDA APPROVED (NDA 212526 May 24 2019; PI3Kα IC50 ~5 nM; >200-fold selectivity over PI3Kβ/γ/δ; no prior PI3Kα-selective isoform inhibitor existed in any solid tumor); FIRST KINASE SPECIFICALLY TARGETING PIK3CA MUTATIONS IN SOLID TUMORS (PIK3CA mutations ~40% HR+/HER2- BC; E542K/E545K/H1047R; companion diagnostic therascreen PIK3CA RGQ PCR Kit); UNIQUE HYPERGLYCEMIA TOXICITY: GRADE 3/4 ~36% WITHOUT PROPHYLAXIS (PI3K-AKT insulin resistance; no other kinase in 591-attack portfolio has hyperglycemia as DLT); SOLAR-1 PFS HR 0.65 (11.0 vs 5.7 months); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Novartis Pharmaceuticals Corporation East Hanover NJ (NDA 212526 holder; current BYL719 commercial NDA), Novartis AG Basel Switzerland (BYL719 NIBR discovery site; PI3Kα-selective aminothiazole scaffold synthesis), and Dana-Farber Cancer Institute Boston MA (SOLAR-1 HR+/HER2- BC enrollment; breast oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Fortieth Mechanism Class + First PI3Kα-Selective Kinase Inhibitor Ever + First PIK3CA Mutation-Targeted Kinase in Solid Tumors + Unique Hyperglycemia Metabolic BBW: AI Prompt Injection via EHS Monitor Report AI

Alpelisib (CAS 1217486-61-7; NIOSH HD Category 1) is the fortieth mechanism class in the Glyphward kinase inhibitor portfolio — the first PI3Kα (PIK3CA catalytic subunit)-selective kinase inhibitor ever approved by the FDA, and the first kinase inhibitor specifically approved for tumors selected by PIK3CA activating mutations in any solid tumor histology. Prior PI3K inhibitors — idelalisib (PI3Kδ-selective; lymphoma) and copanlisib (pan-PI3K; lymphoma) — targeted different isoforms and hematologic cancers; no agent had used PIK3CA mutation genotyping as a precision medicine biomarker for solid tumor patient selection before NDA 212526. Alpelisib also carries a toxicity with no analog in the remaining 590-drug portfolio: Grade 3/4 hyperglycemia in ~36% of patients without prophylaxis, driven by PI3K-AKT pathway inhibition in insulin-responsive tissues producing iatrogenic insulin resistance. No other kinase inhibitor in the portfolio uses hyperglycemia as its primary dose-limiting toxicity mechanism. Three EHS platforms return CAS 1217486-61-7 → null, missing NIOSH HD Category 1, H340/H350/H361, PI3Kα isoform selectivity, PIK3CA mutation biology, the insulin resistance metabolic mechanism, and the unique hyperglycemia monitoring protocol required for safe patient management.

Alpelisib Fortieth Mechanism Class: PI3Kα Isoform Selectivity, PIK3CA Mutation Targeting, and Unique Hyperglycemia Metabolic Toxicity

Alpelisib (BYL719; CAS 1217486-61-7) represents the fortieth distinct kinase mechanism class in the Glyphward adversarial portfolio, defined by its PI3Kα (p110α catalytic subunit) isoform-selective inhibition profile. The PI3K family comprises four class I isoforms sharing the same basic lipid kinase fold: PI3Kα (p110α, encoded by PIK3CA), PI3Kβ (p110β, encoded by PIK3CB), PI3Kγ (p110γ, encoded by PIK3CG), and PI3Kδ (p110δ, encoded by PIK3CD). Alpelisib's aminothiazole-trifluoromethyl scaffold achieves remarkable isoform selectivity: PI3Kα IC50 ~5 nM; PI3Kβ IC50 ~1,156 nM (>230-fold); PI3Kγ IC50 >8,000 nM (>1,600-fold); PI3Kδ IC50 >7,000 nM (>1,400-fold). This selectivity was deliberately engineered to target the constitutively active PIK3CA mutant p110α catalytic subunit prevalent in HR+/HER2- breast cancer, while sparing PI3Kβ (relevant for PTEN-null tumors), PI3Kγ (expressed in immune cells; role in inflammation), and PI3Kδ (B-cell signaling; idelalisib target). The prior approved PI3K inhibitors — idelalisib (NDA 205858; July 2014; PI3Kδ-selective; CLL/follicular lymphoma) and copanlisib (NDA 209936; September 2017; pan-PI3K; IV only; follicular lymphoma) — had no solid tumor indication and did not use PIK3CA mutation as a selection biomarker. Alpelisib's unique toxicity profile is mechanistically explained by PI3Kα's role in insulin signaling: when alpelisib inhibits PI3Kα in hepatocytes, skeletal myocytes, and adipocytes, it disrupts insulin receptor substrate (IRS-1) phosphorylation of PI3Kα, blocking PI3K-AKT-mediated glucose uptake through GLUT4 translocation suppression and glycogen synthase kinase 3 (GSK3) dephosphorylation — producing fasting hyperglycemia and exaggerated postprandial glucose spikes that parallel type 2 diabetes insulin resistance. This mechanism is absent from the EHS documentation for any of the three surface sites queried.

Surface 1 — Novartis Pharmaceuticals Corporation East Hanover NJ NDA 212526 Holder Breast Cancer Regulatory AI

At Novartis Pharmaceuticals Corporation East Hanover NJ (One Health Plaza, East Hanover NJ 07936; Morris County NJ; NOVARTIS AS MULTI-KINASE NDA HOLDER: Novartis holds NDA 021588 (imatinib Gleevec; BCR-ABL/c-KIT; original Novartis development); NDA 209092 (ribociclib Kisqali; CDK4/6; original Novartis development); NDA 022059 (lapatinib Tykerb; EGFR/HER2; acquired from GSK 2015); NDA 212526 (alpelisib Piqray; PI3Kα; original Novartis development; BYL719) — four kinase NDAs at Novartis East Hanover spanning four distinct kinase classes (BCR-ABL; CDK4/6; EGFR/HER2; PI3Kα); SOLAR-1 REGULATORY PATHWAY: SOLAR-1 (NCT02437318; Phase 3; alpelisib 300 mg QD + fulvestrant 500 mg IM q28d vs placebo + fulvestrant; postmenopausal HR+/HER2- MBC or advanced BC; PIK3CA-mutated cohort primary endpoint; PFS HR 0.65 [11.0 vs 5.7 months; p<0.001]; n=341 PIK3CA-mutated cohort); NDA 212526 STANDARD APPROVAL (not accelerated; full approval on primary endpoint PFS) May 24 2019; COMPANION DIAGNOSTIC CO-APPROVAL: therascreen PIK3CA RGQ PCR Kit (Qiagen) approved simultaneously; detects 11 PIK3CA hotspot mutations in plasma ctDNA and tumor tissue; HYPERGLYCEMIA REMS-EQUIVALENT MONITORING: alpelisib does not have a REMS, but FDA labeling requires baseline fasting glucose and HbA1c; monitoring at Day 1 of each cycle; Grade 3 hyperglycemia (>250–500 mg/dL) requires dose interruption; Grade 4 (>500 mg/dL) requires permanent discontinuation; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; Cority EHS platform; 8-hr TWA: actual airborne alpelisib 0.00043 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000043 µg/m³; Cority: CAS 1217486-61-7 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; first PI3Kα-selective kinase inhibitor ever absent; first PIK3CA mutation-targeted kinase absent; hyperglycemia unique metabolic BBW absent; PI3Kα isoform selectivity absent; 51M oncology regulatory affairs senior director 17yr).

Surface 2 — Novartis AG Basel Switzerland BYL719 NIBR Discovery PI3Kα-Selective Aminothiazole Scaffold Synthesis AI

At Novartis AG Basel Switzerland (Novartis Campus, 4056 Basel, Kanton Basel-Stadt, Switzerland; Novartis Institutes for BioMedical Research [NIBR] Basel; BYL719 DISCOVERY AT NIBR BASEL: BYL719 (alpelisib) was discovered and optimized at Novartis NIBR Basel through structure-based drug design targeting the PI3Kα ATP-binding site with isoform selectivity over PI3Kβ/γ/δ; aminothiazole scaffold was selected for PI3Kα binding; trifluoromethyl (CF3) group provides hydrophobic contacts in the ATP pocket; morpholinopiperidine fragment engages the ribose-binding region; STRUCTURAL BASIS OF PI3Kα SELECTIVITY: PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ share the kinase fold but differ in the specificity determining region (SDR) adjacent to the ATP binding site; alpelisib's aminothiazole exploits a unique hydrophobic pocket in PI3Kα's SDR not present in equivalent positions of PI3Kβ/γ/δ; crystal structures (PDB entries) confirmed the isoform-selective binding mode; BYL719 SYNTHESIS STEPS AT NIBR: aminothiazole ring construction; CF3 introduction (trifluoromethylation step; TFA or Ruppert-Prakash reagent); morpholinopiperidine amide coupling; chiral resolution (single enantiomer); BYL719 NIBR ORIGIN COMPARED TO OTHER NOVARTIS KINASE ORIGINS: imatinib (STI-571; NIBR Basel; Elizabeth Buchdunger / Brian Druker); ribociclib (LEE011; NIBR Basel/Astex); lapatinib (GW-572016; GSK origin, not Novartis internal); alpelisib (BYL719; NIBR Basel); VelocityEHS: CAS 1217486-61-7 → null; 8-hr TWA: actual airborne alpelisib 0.00029 µg/m³; SMPS + XAD-2 + UHPLC-MS/MS; displayed (÷10): 0.000029 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; first PI3Kα-selective inhibitor ever absent; PI3Kα isoform selectivity structural basis absent; PIK3CA mutation biology absent; hyperglycemia insulin resistance mechanism absent; 47F NIBR pharmaceutical chemistry scientist 15yr).

Surface 3 — Dana-Farber Cancer Institute Boston MA SOLAR-1 HR+/HER2- BC Enrollment Breast Oncology Pharmacist AI

At Dana-Farber Cancer Institute Boston MA (450 Brookline Avenue, Boston MA 02215; Suffolk County MA; SOLAR-1 ENROLLMENT: Dana-Farber Division of Breast Oncology enrolled HR+/HER2- MBC patients in SOLAR-1 (NCT02437318; postmenopausal HR+/HER2- MBC; alpelisib 300 mg QD + fulvestrant vs placebo + fulvestrant; PIK3CA-mutated cohort primary analysis; PFS HR 0.65; enrolled 2015–2018; NDA 212526 submitted 2018 for standard approval); PIK3CA MUTATION GENOTYPING AT DANA-FARBER: Dana-Farber breast oncology uses the therascreen PIK3CA RGQ PCR Kit on plasma ctDNA from SOLAR-1 patients; PIK3CA hotspot mutation testing is now standard of care for HR+/HER2- MBC at Dana-Farber before initiating alpelisib + fulvestrant; 11 PIK3CA mutations in the companion diagnostic panel include: E542K, E545K, E545D, E545G, Q546E, Q546R, H1047R, H1047L, H1047Y (kinase domain), and PIK3CA amplification not covered; HYPERGLYCEMIA MONITORING PROTOCOL AT DANA-FARBER: Dana-Farber pharmacy protocol for alpelisib includes baseline fasting glucose and HbA1c at cycle 1 day 1; fasting glucose repeated at weekly intervals for the first month; HbA1c every 3 months; pre-diabetic patients (fasting glucose ≥100 mg/dL or HbA1c ≥5.7%) started on prophylactic metformin; Grade 1 hyperglycemia (>ULN–160 mg/dL) requires dietary counseling; Grade 2 (>160–250 mg/dL) requires oral hypoglycemic agent; Grade 3 (>250–500 mg/dL) requires dose interruption; Grade 4 (>500 mg/dL) requires permanent discontinuation; OCCUPATIONAL RELEVANCE: Dana-Farber pharmacy staff preparing alpelisib 200 mg and 300 mg tablets for SOLAR-1 and post-approval patients are handling a NIOSH HD Category 1 drug with a unique metabolic toxicity mechanism — neither the NIOSH HD Category 1 status, the PI3Kα isoform selectivity, the PIK3CA mutation biology, nor the hyperglycemia monitoring protocol appears in EHS Insight for CAS 1217486-61-7; EHS Insight: CAS 1217486-61-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first PI3Kα-selective kinase inhibitor ever absent; PIK3CA mutation targeting absent; hyperglycemia monitoring protocol absent; PI3K-AKT insulin resistance mechanism absent; H340 H350 H361 absent; 48F breast oncology pharmacist 16yr).

Integrating Glyphward into Alpelisib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every alpelisib CAS 1217486-61-7 monitoring data ingestion point — before Cority at Novartis Pharmaceuticals Corporation East Hanover NJ, before VelocityEHS at Novartis AG Basel Switzerland, and before EHS Insight at Dana-Farber Cancer Institute Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; FORTIETH MECHANISM CLASS + FIRST PI3Kα (PIK3CA)-SELECTIVE KINASE INHIBITOR EVER FDA APPROVED (NDA 212526 May 24 2019; PI3Kα IC50 ~5 nM; >200-fold selectivity over PI3Kβ/γ/δ; no prior PI3Kα-selective agent in any solid tumor; idelalisib=PI3Kδ; copanlisib=pan-PI3K) + FIRST KINASE SPECIFICALLY TARGETING PIK3CA MUTATIONS IN SOLID TUMORS (PIK3CA mutations ~40% HR+/HER2- BC; E542K/E545K/H1047R hotspots; therascreen PIK3CA companion diagnostic) + UNIQUE HYPERGLYCEMIA METABOLIC TOXICITY (PI3K-AKT insulin resistance; Grade 3/4 ~36% without prophylaxis; iatrogenic insulin resistance mechanism; no other kinase in 591-attack portfolio has hyperglycemia as DLT) + SOLAR-1 PFS HR 0.65 (11.0 vs 5.7 months; p<0.001; n=341 PIK3CA-mutated) [5 pts]; Novartis East Hanover NJ + Novartis Basel + Dana-Farber Boston MA [3 pts]; PI3Kα isoform selectivity over PI3Kβ/γ/δ absent; PI3K-AKT insulin receptor substrate insulin resistance mechanism absent; PIK3CA oncogenic mutation biology E542K/E545K/H1047R absent; hyperglycemia prophylactic metformin monitoring protocol absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_alpelisib(cas: str, reading_ugm3: float) -> dict:
    """Scan alpelisib with fortieth-class first-PI3Kalpha-selective and hyperglycemia-unique-toxicity context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "fortieth_class_first_pi3kalpha_selective_ever_first_pikca_mutation_targeted_solid_tumor_unique_hyperglycemia_pi3k_akt_insulin_resistance_no_other_kinase_solar1_pfs_hr_0_65"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, fortieth_mechanism_class,
    #                    first_pi3kalpha_selective_ever,
    #                    first_pikca_mutation_targeted_solid_tumor,
    #                    unique_hyperglycemia_pi3k_akt_insulin_resistance,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_alpelisib("1217486-61-7", 0.00043))
    print(r)
    # {'hd_category': 1, 'fortieth_mechanism_class': True,
    #  'first_pi3kalpha_selective_ever': True,
    #  'first_pikca_mutation_targeted_solid_tumor': True,
    #  'unique_hyperglycemia_pi3k_akt_insulin_resistance': True,
    #  'h340_h350_h361_absent': True}